Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Jarida la Kliniki la Awamu ya II× | Jaribio la Kliniki la Awamu ya I× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1960s–1970s (formalised in US federal drug regulation) | 1960s (formal regulatory framework established ~1963–1970s) |
| Mwanzilishi≠ | U.S. Food and Drug Administration / ICH E8 guidelines (institutionalised framework) | Regulatory and clinical pharmacology community; formalized in U.S. FDA IND regulations (1963) and ICH guidelines |
| Aina | Interventional clinical study design | Interventional clinical study design |
| Chanzo asilia≠ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185392 | Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI ↗ |
| Majina mbadala | Phase 2 trial, Phase II study, early efficacy trial, proof-of-concept trial | Phase 1 trial, first-in-human study, FIH study, dose-escalation study |
| Zinazohusiana | 6 | 6 |
| Muhtasari≠ | A Phase II clinical trial is the second stage in the drug or intervention development pipeline, conducted after Phase I safety testing. Its primary goal is to assess whether the intervention shows preliminary efficacy signals in a relevant patient population at the dose established in Phase I, while continuing to characterise the safety and tolerability profile. Phase II trials are generally smaller than Phase III confirmatory trials and serve as critical go/no-go decision points before large-scale investment. | A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials. |
| ScholarGateSeti ya data ↗ |
|
|